research Efficacy and safety of docetaxel in the elderly
Docetaxel is safe and works well for older people with cancer, with manageable side effects.
Search
for
Sort by
Research
990-1000 / 1000+ results research FPRL1 Receptor Agonist Peptides Prevent Etoposide-Induced Alopecia in Neonatal Rats
Certain peptides can prevent hair loss in young rats caused by a cancer drug.
research Advancing human adipose-derived mesenchymal stem cell-derived exosomes for androgenetic alopecia: Appraisal and methodological recommendations
Exosome-based therapies could help treat hair loss, but more research is needed.
research Preparation and properties of finasteride loaded poly(propylene carbonate maleate) sustained release microspheres
PPCM microspheres can effectively release finasteride over 42 days.
research DHEA : why, when, and how much ? D’après la conférence de Bruno Allolio (Wuerzburg), 50e Journées internationales d’endocrinologie clinique Henri-Pierre KLOTZ, septembre 2007
DHEA supplementation may improve quality of life, neuropsychological functions, and sexual satisfaction in individuals with adrenal insufficiency, but more research is needed to confirm its safety and effectiveness.
research Treatment of monilethrix with oral minoxidil
Oral minoxidil shows promise in treating monilethrix-related hair loss.
research Clinical Features and Current Therapeutic Approaches to Monilethrix: A Systematic Review
Topical and oral minoxidil are the best treatments for monilethrix.
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
The herbal extract is as effective and safe as 3% minoxidil for treating hair loss.
research INTRODUCING ELECTROMAGNETIC ENERGY FROM HYDROCOLLOID WOUND DRESSING PASTE PENETRATING A GLASS BARRIER DISRUPTING HUMAN SKIN LIPID DROPLETS SIZE AND MEMBRANES: POSSIBLE IMPLICATIONS IN CANCER CELLS GENESIS AND/OR CURE
Electromagnetic energy from wound dressing paste can disrupt skin lipid droplets, possibly affecting cancer development.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.